Strategic Transformation - AngioDynamics is pursuing larger markets through active portfolio management, relying on technology and innovation to produce measurable patient outcomes[5] - The company is focusing resource development in areas that offer the best opportunities for success[6] - Portfolio transformation and strength is driven by R&D, M&A, and Clinical & Regulatory efforts, combined with top talent to drive value[7] Peripheral Atherectomy - The US addressable market for Peripheral Atherectomy is \$555 million, with mechanical atherectomy accounting for 77% and laser atherectomy for 23%[19] - AngioDynamics launched the Auryon System in 2021, providing access to the peripheral atherectomy market[9] Thrombus Management - AngioDynamics is targeting a \$77 million addressable market in the Right Atrium with its AngioVac system[28] - The company is planning to launch a multi-purpose mechanical aspiration device to compete in the broader DVT & PE markets, which are valued at \$1.3 billion and \$1.6 billion respectively[28, 33] - There are 208,000 Iliofemoral Deep Vein Thrombosis cases and 171,000 High-risk & intermediate-risk Pulmonary Embolism cases[25] Irreversible Electroporation (NanoKnife) - In 2020, there were 1,256,970 new cancer cases[40] - 38% of prostate cancer patients are ideal candidates for focal therapy[48] Financial Performance (First Half FY2021) - AngioDynamics reported revenue of \$143.0 million, a 5.1% increase year-over-year[53] - Adjusted EBITDA was \$9.6 million[53] - AngioVac grew 34% and NanoKnife Disposables grew 12%[55] - Auryon revenue contribution was \$3.2 million[55]

AngioDynamics, Inc. (NASDAQ:ANGO) Q2 2021 Earnings Conference Call January 7, 2021 8:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Steve Trowbridge - Executive Vice President and Chief Financial Officer Conference Call Participants Jayson Bedford - Raymond James Matthew Mishan - KeyBanc Capital Markets Bill Plovanic - Canaccord Genuity Operator Good morning, and welcome to the AngioDynamics Fiscal Year 2021 Second Quarter Earnings Call. At this time, all participants ar ...

Financial Performance - AngioDynamics' Q2 FY2021 revenue increased by 40% year-over-year, reaching $72770 thousand compared to $70003 thousand in Q2 FY2020[8] - Gross margin for Q2 FY2021 was 552%, a decrease of 410 basis points compared to 593% in Q2 FY2020[8, 12] - Adjusted EPS for Q2 FY2021 was $001, a decrease of $005 from $006 in Q2 FY2020[8] - Adjusted EBITDA for Q2 FY2021 was $5158 thousand, a decrease of $1252 thousand from $6410 thousand in Q2 FY2020[8] - Free cash flow for Q2 FY2021 was $10087 thousand, an increase of $6773 thousand from $3314 thousand in Q2 FY2020[8] - AngioDynamics reaffirms FY2021 revenue guidance of $278 million to $284 million[7] Product Line Performance - NanoKnife disposable growth was 76% in the US and 30% worldwide[6] - AngioVac experienced growth of 24%[6, 9] - Vascular Access Midlines grew 17% in Q2 FY2021 and 53% year-to-date[10] - NanoKnife Capital experienced a decline of 50% in Q2 FY2021[11] Thrombus Management Portfolio - AngioDynamics is progressing toward the planned launch of a multi-purpose mechanical aspiration thrombectomy device in calendar 2021[6, 20] - AngioVac's use is currently focused on the Right Heart, which is a $77 million addressable market[20]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 AngioDynamics, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3146460 (State or other juris ...

AngioDynamics, Inc. (NASDAQ:ANGO) Q1 2021 Results Conference Call September 29, 2020 8:00 AM ET Company Participants Jim Clemmer - President and CEO Steve Trowbridge - EVP and CFO Conference Call Participants Matthew Mishan - KeyBanc Capital Markets Jayson Bedford - Raymond James Cecilia Furlong - Canaccord Genuity Operator Good morning, and welcome to the AngioDynamics Fiscal Year 2021 First Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | --- | |------------------------------------------|---------------------------------|-----------------------------------------------------------|---------------------------------------- ...